{"issuance_frequency":"","notes_translated":{"fr":"Le Relevé des maladies transmissibles au Canada est une publication bilingue et libre d'accès revue par un comité de lecture portant sur la prévention et le contrôle des maladies infectieuses nouvelles et tenaces.\r\n","en":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"P1M","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","metadata_created":"2020-04-06T19:00:37.239412","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2020-04-06T19:40:36.540428","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2020-04-06","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["vaccin","Comité consultatif national sur l’immunisation","CCNI","immunisation","VRS","virus respiratoire syncytial","oreillons","éclosion","incidence","vaccination","vaccin ROR","enquête","immunité","Manitoba","rougeole","santé en voyage","surveillance","élimination de la rougeole","vaccination","tuberculose","Mycobacterium tuberculosis","épreuve de sensibilité aux médicaments","résistant à l'isoniazide","multirésistant","réticence à la vaccination","entrevue motivationnelle","acceptation de la vaccination","recours à la vaccination","préoccupations parentales","covid","coronavirus"],"en":["Vaccine","National Advisory Committee on Immunization","NACI","immunization","RSV","respiratory syncytial virus","mumps","outbreak","incidence","vaccination","MMR vaccine","investigation","immunity","Manitoba","measles","travel health","surveillance","measles elimination","vaccination","tuberculosis","Mycobacterium tuberculosis","drug susceptibility test","isoniazid-resistant","multidrug-resistant","vaccine hesitancy","motivational interviewing","vaccine acceptance","vaccine uptake","parental concerns","covid","coronavirus"]},"relationships_as_object":[],"creator_user_id":"4cfa9a9c-1d95-40eb-86f9-bc0c8ec45d1f","title_translated":{"fr":"RMTC : Volume 46-4 -avril 2020 : Virus respiratoire syncytial (VRS)","en":"CCDR: Volume 46-4 -April 2020: Respiratory syncytial virus (RSV)"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"e19a38ac-44eb-4064-988f-5e069b322f0a","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46-4 -avril 2020 : Virus respiratoire syncytial (VRS)","en":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)","language":["en"],"created":"2020-04-06T19:00:37.425718","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020.html","last_modified":null,"position":0,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"64caa20f-efac-41e4-8c19-1af5a7a9f5c2","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46-4 -avril 2020 : Virus respiratoire syncytial (VRS)","en":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)","language":["fr"],"created":"2020-04-06T19:00:37.425726","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020.html","last_modified":null,"position":1,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"80cacd77-fc91-489d-9af3-f100f630f6c2","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46-4 -avril 2020 : Virus respiratoire syncytial (VRS)","en":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)","language":["fr"],"created":"2020-04-06T19:00:37.425729","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04f-fra.pdf","last_modified":null,"position":2,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"92209ed1-9e7e-4496-9b22-faa0726e3e7c","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46-4 -avril 2020 : Virus respiratoire syncytial (VRS)","en":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-04 -April 2020: Respiratory syncytial virus (RSV)","language":["en"],"created":"2020-04-06T19:00:37.425732","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04-eng.pdf","last_modified":null,"position":3,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"351b41d2-42a6-4785-bbb9-38fdf961c2ad","related_relationship":"","name_translated":{"fr":"Aperçu de la filière de candidats vaccins contre le virus respiratoire syncytial au Canada","en":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada","language":["en"],"created":"2020-04-06T19:00:37.425735","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-1-challenges-developing-vaccine-respiratory-syncytial-virus.html","last_modified":null,"position":4,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"626e0c1e-5805-47fe-b8dd-15a45312e70f","related_relationship":"","name_translated":{"fr":"Aperçu de la filière de candidats vaccins contre le virus respiratoire syncytial au Canada","en":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada","language":["fr"],"created":"2020-04-06T19:00:37.425753","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-1-defis-matiere-creation-vaccin-contre-virus-respiratoire-syncytial.html","last_modified":null,"position":5,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c10d8287-04cc-4bdb-81ae-4f7520510a4d","related_relationship":"","name_translated":{"fr":"Aperçu de la filière de candidats vaccins contre le virus respiratoire syncytial au Canada","en":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada","language":["en"],"created":"2020-04-06T19:00:37.425756","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a01-eng.pdf","last_modified":null,"position":6,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5d90e966-eb2f-4f24-9c37-218f75ee8795","related_relationship":"","name_translated":{"fr":"Aperçu de la filière de candidats vaccins contre le virus respiratoire syncytial au Canada","en":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada","language":["fr"],"created":"2020-04-06T19:00:37.425758","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a01f-fra.pdf","last_modified":null,"position":7,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"de119e71-6f72-4d35-a60e-325011767fd2","related_relationship":"","name_translated":{"fr":"Analyse des lacunes visant à évaluer le niveau de préparation des Canadiens à l’introduction des vaccins contre le virus respiratoire syncytial : compte rendu d’une retraite d’experts","en":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat","language":["en"],"created":"2020-04-06T19:00:37.425761","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-2-report-canada-readiness-rsv-vaccines.html","last_modified":null,"position":8,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"3e186865-529c-4969-8654-8531b7d2832e","related_relationship":"","name_translated":{"fr":"Analyse des lacunes visant à évaluer le niveau de préparation des Canadiens à l’introduction des vaccins contre le virus respiratoire syncytial : compte rendu d’une retraite d’experts ","en":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat","language":["fr"],"created":"2020-04-06T19:00:37.425763","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-2-rapport-preparation-canada-vaccins-vrs.html","last_modified":null,"position":9,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"7ac66110-f21b-4061-a211-3a8c00741879","related_relationship":"","name_translated":{"fr":"Analyse des lacunes visant à évaluer le niveau de préparation des Canadiens à l’introduction des vaccins contre le virus respiratoire syncytial : compte rendu d’une retraite d’experts","en":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat","language":["en"],"created":"2020-04-06T19:00:37.425766","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a02-eng.pdf","last_modified":null,"position":10,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"927eec28-8a05-4dee-953c-9383460f43db","related_relationship":"","name_translated":{"fr":"Analyse des lacunes visant à évaluer le niveau de préparation des Canadiens à l’introduction des vaccins contre le virus respiratoire syncytial : compte rendu d’une retraite d’experts","en":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat","language":["fr"],"created":"2020-04-06T19:00:37.425768","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a02f-fra.pdf","last_modified":null,"position":11,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6fa17dc1-4d07-44d8-80f9-9b042342248e","related_relationship":"","name_translated":{"fr":"Infographique: Sommaire des produits de vaccins contre le VRS en phase avancée de développement","en":"Infographic: Summary of RSV vaccine products in late-stage development"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Summary of RSV vaccine products in late-stage development","language":["en"],"created":"2020-04-06T19:00:37.425770","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-2a-respiratory-syncytial-virus-vaccine-products.html","last_modified":null,"position":12,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f9d50d0d-265e-4412-8316-4c25a3700446","related_relationship":"","name_translated":{"fr":"Infographique: Sommaire des produits de vaccins contre le VRS en phase avancée de développement","en":"Infographic: Summary of RSV vaccine products in late-stage development"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Summary of RSV vaccine products in late-stage development","language":["fr"],"created":"2020-04-06T19:00:37.425773","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-2a-produits-vaccinaux-contre-virus-respiratoire-syncytial.html","last_modified":null,"position":13,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"b87349dc-3254-4b1f-b04f-224f15d8c012","related_relationship":"","name_translated":{"fr":"Infographique: Sommaire des produits de vaccins contre le VRS en phase avancée de développement","en":"Infographic: Summary of RSV vaccine products in late-stage development"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Summary of RSV vaccine products in late-stage development","language":["en"],"created":"2020-04-06T19:00:37.425775","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a02a-eng.pdf","last_modified":null,"position":14,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f38cbead-29a1-4a43-9dad-0c75ddb5c480","related_relationship":"","name_translated":{"fr":"Infographique: Sommaire des produits de vaccins contre le VRS en phase avancée de développement","en":"Infographic: Summary of RSV vaccine products in late-stage development"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Summary of RSV vaccine products in late-stage development","language":["fr"],"created":"2020-04-06T19:00:37.425778","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a02af-fra.pdf","last_modified":null,"position":15,"revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"461ae651-e3ad-43fe-b680-9ce108d2ec1c","related_relationship":"","name_translated":{"fr":"Importante éclosion communautaire d’oreillons au Manitoba (Canada) entre septembre 2016 et décembre 2018","en":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018","language":["en"],"created":"2020-04-06T19:10:38.543245","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-3-mumps-outbreak-manitoba-canada-2018-2019.html","last_modified":null,"position":16,"revision_id":"939816ed-5563-49dd-a809-dd178d9f7e86","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c1688ee9-782c-45d6-b285-adfe669bc284","related_relationship":"","name_translated":{"fr":"Importante éclosion communautaire d’oreillons au Manitoba (Canada) entre septembre 2016 et décembre 2018 ","en":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018 ","language":["fr"],"created":"2020-04-06T19:10:38.543254","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-3-eclosion-oreillons-manitoba-canada-2018-2019.html","last_modified":null,"position":17,"revision_id":"939816ed-5563-49dd-a809-dd178d9f7e86","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"7c490b83-2fd6-4f77-ab3f-f24c37ebe6fe","related_relationship":"","name_translated":{"fr":"Importante éclosion communautaire d’oreillons au Manitoba (Canada) entre septembre 2016 et décembre 2018 ","en":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018 "},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018 ","language":["en"],"created":"2020-04-06T19:10:38.543257","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a03-eng.pdf","last_modified":null,"position":18,"revision_id":"939816ed-5563-49dd-a809-dd178d9f7e86","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4fbe57c1-0153-4d84-854d-6e3b9d804fd8","related_relationship":"","name_translated":{"fr":"Importante éclosion communautaire d’oreillons au Manitoba (Canada) entre septembre 2016 et décembre 2018","en":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018","language":["fr"],"created":"2020-04-06T19:20:35.687354","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a03f-fra.pdf","last_modified":null,"position":19,"revision_id":"58cb47d5-93e1-4d0e-a5c5-b3463a2c3732","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f7f215a0-9450-49ad-9cde-25e44cf59529","related_relationship":"","name_translated":{"fr":"Surveillance de la rougeole au Canada : 2018","en":"Measles surveillance in Canada: 2018 "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Measles surveillance in Canada: 2018 ","language":["en"],"created":"2020-04-06T19:20:35.687361","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-4-report-measles-canada-2018.html","last_modified":null,"position":20,"revision_id":"58cb47d5-93e1-4d0e-a5c5-b3463a2c3732","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"73e01823-80f1-4d14-b2fe-db8b4f4108ee","related_relationship":"","name_translated":{"fr":"Surveillance de la rougeole au Canada : 2018","en":"Measles surveillance in Canada: 2018"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Measles surveillance in Canada: 2018","language":["fr"],"created":"2020-04-06T19:20:35.687364","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-4-rapport-rougeole-canada-2018.html","last_modified":null,"position":21,"revision_id":"58cb47d5-93e1-4d0e-a5c5-b3463a2c3732","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ab925911-a673-458c-af99-a969ec5d5a0e","related_relationship":"","name_translated":{"fr":"Surveillance de la rougeole au Canada : 2018 ","en":"Measles surveillance in Canada: 2018"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Measles surveillance in Canada: 2018","language":["en"],"created":"2020-04-06T19:20:35.687366","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a04-eng.pdf","last_modified":null,"position":22,"revision_id":"58cb47d5-93e1-4d0e-a5c5-b3463a2c3732","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"032bd1ab-ce78-440c-9aff-9d3b575953d9","related_relationship":"","name_translated":{"fr":"Surveillance de la rougeole au Canada : 2018","en":"Measles surveillance in Canada: 2018"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Measles surveillance in Canada: 2018","language":["fr"],"created":"2020-04-06T19:30:38.841915","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a04f-fra.pdf","last_modified":null,"position":23,"revision_id":"8048c016-08d7-4f56-bfb4-12985eee83f3","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"00e0abbe-5c04-42e1-9379-8cd54d268437","related_relationship":"","name_translated":{"fr":"Facteurs de risque associés à la tuberculose pharmacorésistante dans un centre de référence situé à Toronto (Ontario) au Canada : 2010 à 2016","en":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016","language":["en"],"created":"2020-04-06T19:30:38.841922","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-5-clinical-risk-factors-drug-resistant-tuberculosis-ontario-canada-2010-2016.html","last_modified":null,"position":24,"revision_id":"8048c016-08d7-4f56-bfb4-12985eee83f3","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"939aed98-b7c2-4056-92ab-f7b59ba22daa","related_relationship":"","name_translated":{"fr":"Facteurs de risque associés à la tuberculose pharmacorésistante dans un centre de référence situé à Toronto (Ontario) au Canada : 2010 à 2016","en":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016","language":["fr"],"created":"2020-04-06T19:30:38.841925","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-5-facteurs-risque-cliniques-tuberculose-multiresistante-ontario-canada-2010-2016.html","last_modified":null,"position":25,"revision_id":"8048c016-08d7-4f56-bfb4-12985eee83f3","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"65b64c1a-de1c-4d43-8a4b-70650b60b3c7","related_relationship":"","name_translated":{"fr":"Facteurs de risque associés à la tuberculose pharmacorésistante dans un centre de référence situé à Toronto (Ontario) au Canada : 2010 à 2016","en":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016","language":["en"],"created":"2020-04-06T19:30:38.841927","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a05-eng.pdf","last_modified":null,"position":26,"revision_id":"8048c016-08d7-4f56-bfb4-12985eee83f3","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"05d3f349-640d-4bd6-841f-bdb0a9f51570","related_relationship":"","name_translated":{"fr":"Facteurs de risque associés à la tuberculose pharmacorésistante dans un centre de référence situé à Toronto (Ontario) au Canada : 2010 à 2016","en":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016","language":["fr"],"created":"2020-04-06T19:30:38.841930","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a05f-fra.pdf","last_modified":null,"position":27,"revision_id":"8048c016-08d7-4f56-bfb4-12985eee83f3","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"2035d7a1-c587-4d04-8669-3bd484a38117","related_relationship":"","name_translated":{"fr":"L’entrevue motivationnelle : un outil particulièrement efficace pour atténuer la réticence à la vaccination","en":"Motivational interviewing: A powerful tool to address vaccine hesitancy"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Motivational interviewing: A powerful tool to address vaccine hesitancy","language":["en"],"created":"2020-04-06T19:30:38.841932","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-6-canvax-addressing-vaccine-hesitancy.html","last_modified":null,"position":28,"revision_id":"8048c016-08d7-4f56-bfb4-12985eee83f3","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"20be9532-9f90-47a2-b6dc-6bb17d0d43fc","related_relationship":"","name_translated":{"fr":"L’entrevue motivationnelle : un outil particulièrement efficace pour atténuer la réticence à la vaccination","en":"Motivational interviewing: A powerful tool to address vaccine hesitancy"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Motivational interviewing: A powerful tool to address vaccine hesitancy","language":["fr"],"created":"2020-04-06T19:30:38.841934","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-6-canvax-vaincre-reticence-vaccination.html","last_modified":null,"position":29,"revision_id":"8048c016-08d7-4f56-bfb4-12985eee83f3","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"373f17e1-2c85-4412-b3d3-df25c12b01a2","related_relationship":"","name_translated":{"fr":"L’entrevue motivationnelle : un outil particulièrement efficace pour atténuer la réticence à la vaccination","en":"Motivational interviewing: A powerful tool to address vaccine hesitancy"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Motivational interviewing: A powerful tool to address vaccine hesitancy","language":["en"],"created":"2020-04-06T19:40:36.610563","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a06-eng.pdf","last_modified":null,"position":30,"revision_id":"39da4c02-f25e-48e8-9fc8-8ae1670472e4","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"aa9ca478-a783-48f0-bcaf-db36975e78e6","related_relationship":"","name_translated":{"fr":"L’entrevue motivationnelle : un outil particulièrement efficace pour atténuer la réticence à la vaccination","en":"Motivational interviewing: A powerful tool to address vaccine hesitancy"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Motivational interviewing: A powerful tool to address vaccine hesitancy","language":["fr"],"created":"2020-04-06T19:40:36.610570","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a06f-fra.pdf","last_modified":null,"position":31,"revision_id":"39da4c02-f25e-48e8-9fc8-8ae1670472e4","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"65b7b55a-5717-4c1c-9187-d7bc8069325b","related_relationship":"","name_translated":{"fr":"COVID-19 : L’ibuprofène ne doit pas être utilisé pour traiter les symptômes, préviennent médecins et chercheurs; Maladie à coronavirus (COVID-19)","en":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)","language":["en"],"created":"2020-04-06T19:40:36.610573","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/article-7-id-news.html","last_modified":null,"position":32,"revision_id":"39da4c02-f25e-48e8-9fc8-8ae1670472e4","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"99c3026e-4b85-49fb-8e93-77a5d1380e8e","related_relationship":"","name_translated":{"fr":"COVID-19 : L’ibuprofène ne doit pas être utilisé pour traiter les symptômes, préviennent médecins et chercheurs; Maladie à coronavirus (COVID-19)","en":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)","language":["fr"],"created":"2020-04-06T19:40:36.610575","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-4-2-avril-2020/article-7-actualites-maladies-infectieuses.html","last_modified":null,"position":33,"revision_id":"39da4c02-f25e-48e8-9fc8-8ae1670472e4","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"d387a64f-f324-484b-9325-e573ada66df6","related_relationship":"","name_translated":{"fr":"COVID-19 : L’ibuprofène ne doit pas être utilisé pour traiter les symptômes, préviennent médecins et chercheurs; Maladie à coronavirus (COVID-19)","en":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)","language":["en"],"created":"2020-04-06T19:40:36.610577","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a07-eng.pdf","last_modified":null,"position":34,"revision_id":"39da4c02-f25e-48e8-9fc8-8ae1670472e4","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"3427c9e6-eda2-459a-bf19-6b31037e25eb","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"32d621d5-7b61-4dab-bc94-bdf6587c5dcc","related_relationship":"","name_translated":{"fr":"COVID-19 : L’ibuprofène ne doit pas être utilisé pour traiter les symptômes, préviennent médecins et chercheurs; Maladie à coronavirus (COVID-19)","en":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists; Coronavirus disease (COVID-19)","language":["fr"],"created":"2020-04-06T19:40:36.610579","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-4-april-2-2020/ccdrv46i04a07f-fra.pdf","last_modified":null,"position":35,"revision_id":"39da4c02-f25e-48e8-9fc8-8ae1670472e4","resource_type":"website"}],"place_of_publication":[],"num_resources":36,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Agence de la santé publique du Canada","en":"Public Health Agency of Canada"},"date_published":"2020-04-02 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:57.068700","title":"Public Health Agency of Canada | Agence de la santé publique du Canada","name":"phac-aspc","is_organization":true,"state":"active","image_url":"","revision_id":"96161da6-edc7-4d1d-99e0-baac9df7b3b9","type":"organization","id":"1C71053B-AA64-4646-956B-41631C396018","approval_status":"approved"},"name":"3427c9e6-eda2-459a-bf19-6b31037e25eb","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases.","owner_org":"1C71053B-AA64-4646-956B-41631C396018","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"CCDR: Volume 46-4 -April 2020: Respiratory syncytial virus (RSV)","revision_id":"d3c15758-819c-47be-aec5-66dad78f05c6"}